Optimal Management of Residual Cardiovascular Risks After Acute Coronary Syndrome

Cardiology Discovery · Published 2026-07-07 · DOI 10.1097/cd9.0000000000000201

Free full text

Authors (4)

Ying Shen, Jieyun You, Qi Zhang, Weifeng Shen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shen, Y., You, J., Zhang, Q., et al. (2026). Optimal Management of Residual Cardiovascular Risks After Acute Coronary Syndrome. Cardiology Discovery. https://doi.org/10.1097/cd9.0000000000000201

Related articles

• A National Registry to Improve the Quality of Care for Patients With Acute Coronary Syndrome and Diabetes: Protocol for the China Diabetes Cardiovascular (CDCV) Project · Cardiology Discovery · 2025 · Same journal
• Modern Understanding in the Causes and Prevention of Heart Failure · Cardiology Discovery · 2025 · Same journal
• Innovative Approaches in the Early Detection of Heart Failure · Cardiology Discovery · 2025 · Same journal
• Atherosclerotic Plaque vs. Coronary Stenosis: Redefining the Drivers of Coronary Artery Disease—Comment on the Lancet Commission · Cardiology Discovery · 2026 · Same journal
• Comparative Evaluation of Cardiac Sarcoidosis, Giant Cell Myocarditis, and Arrhythmogenic Right Ventricular Cardiomyopathy on Cardiac Magnetic Resonance · Cardiology Discovery · 2026 · Same journal
• The Heart-Brain Axis: Key Concepts in Neurocardiology · Cardiology Discovery · 2025 · Same journal
• Combination of the LPS/TLR4 Pathway and Fecal Metabolomics Analysis Reveals the Chronic Inflammatory Mechanism of Early Atherosclerosis in Tibetan Miniature Pigs · Cardiology Discovery · 2025 · Same journal
• Cardiocerebral Protective Effects of Nicorandil Beyond Antiangina: Insights From a Series of Real-World Studies · Cardiology Discovery · 2025 · Same journal
• CSC Guidelines for Percutaneous Coronary Intervention (2025) · Cardiology Discovery · 2026 · Same journal
• One- vs. Six‑Month Dual Antiplatelet Therapy After Biodegradable Polymer Stent Implantation in Patients With Coronary Artery Disease and High Bleeding Risk: Rationale and Design of the Randomized TARGET SAFE Trial · Cardiology Discovery · 2026 · Same journal